专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

41. 发明申请

US20040171676A1 L-ascorbic acid-2-o-maleic acid-a-tocopherol diester 1-propanol adduct and process for producing the same 有权
公开(公告)号：US20040171676A1
公开(公告)日：2004-09-02
申请号：US10479145
申请日：2003-11-25
发明人： Kazumi Ogata , Noriko Saito , Kazuhiko Yamada , Genta Maruyama
IPC分类号： A61K031/375 , C07D45/02
CPC分类号： C07H19/23 , C07D407/12
摘要： L-Ascorbic acid-2-O-maleic acid-null-tocopherol diester.1-propanol adduct or its pharmacologically acceptable salt; cosmetic components, antioxidants, radical scavengers, anti-inflammatory agents and elastase inhibitors containing the same as the active ingredient; and a process for producing the above-described adduct characterized by comprising extracting a solution containing L-ascorbic acid-2-O-maleic acid-null-tocopherol diester with a solvent, distilling off the solvent, and adding to the residue 1-propanol mixed with an organic solvent followed by crystallization.

42. 发明申请

US20040167077A1 Novel ascorbic acid compounds, methods of synthesis and application use thereof 失效
标题翻译：新型抗坏血酸化合物，其合成及应用方法
公开(公告)号：US20040167077A1
公开(公告)日：2004-08-26
申请号：US10781296
申请日：2004-02-18
发明人： Waheed M. Roomi , Shrirang Netke , Vadim Ivanov , Aleksandra Niedzwiecki , Matthias Rath
IPC分类号： A61K038/04 , A61K031/4025 , A61K031/375
CPC分类号： C07D307/33 , A61K31/34 , A61K31/375 , A61K2300/00
摘要： A composition of L-ascorbic acid derivatives is described comprising L-ascorbic acid and lysine or lysine moieties, wherein L-ascorbic acid is covalently bound to the lysine or lysine moieties. The composition so described is used to prevent the degradation of extracellular matrix, stabilize connective tissue, is used to as an antioxident, and is used for treating damage to skin comprising applying the topical composition to the skin.
摘要翻译：描述了L-抗坏血酸衍生物的组合物，其包含L-抗坏血酸和赖氨酸或赖氨酸部分，其中L-抗坏血酸与赖氨酸或赖氨酸部分共价结合。所描述的组合物用于防止细胞外基质的降解，稳定结缔组织，用作抗氧化剂，并用于治疗对皮肤的损伤，包括将局部组合物施用于皮肤。

43. 发明申请

US20040143005A1 Colon cleansing compositions and methods 有权
标题翻译：结肠清洗组合物和方法
公开(公告)号：US20040143005A1
公开(公告)日：2004-07-22
申请号：US10693328
申请日：2003-10-24
申请人： NORGINE EUROPE BV
发明人： Norman Barras , Ian David Cox
IPC分类号： A61K031/375 , A61K031/08
CPC分类号： A61K9/009 , A61K9/0095 , A61K31/375 , A61K31/765 , A61K33/00 , A61K33/04 , A61K33/06 , A61K33/14 , A61K45/06 , Y10S514/892 , A61K2300/00
摘要： A composition comprising, per litre of aqueous solution, from 30 to 350 g polyethylene glycol, from 3 to 20 g of an ascorbic acid component selected form the group consisting of ascorbic acid, a salt of ascorbic acid, or a mixture thereof, an alkali metal or alkaline earth metal sulphate, preferably from 1 to 15 g thereof, and optionally one or more electrolytes selected from sodium chloride, potassium chloride, and sodium hydrogen carbonate, and preferably also comprising flavourings, is effective in cleansing the gut in preparation for a endoscopy, especially colonoscopy. It is safer than conventional sodium phosphate-based gut cleansing compositions, and hence can be used for patients who would be at risk with sodium phosphate-based compositions, and is better tolerated than conventional PEG-based compositions, leading to better patient compliance and enabling effective out-patient use.
摘要翻译：一种组合物，其包含每升水溶液30至350g聚乙二醇，3至20g抗坏血酸组分，选自抗坏血酸，抗坏血酸盐或其混合物，碱金属或碱土金属硫酸盐，优选其1至15g，以及任选的一种或多种选自氯化钠，氯化钾和碳酸氢钠的电解质，并且优选还包含调味剂，在清洁肠道中有效，以制备内镜检查，特别是结肠镜检查。它比常规磷酸钠基肠清洁组合物更安全，因此可用于使用基于磷酸钠的组合物处于危险中的患者，并且比常规的基于PEG的组合物更耐受，导致更好的患者依从性和使能有效的门诊使用。

44. 发明申请

US20040105849A1 Treatment for SMA disease 审中-公开
标题翻译：治疗SMA病
公开(公告)号：US20040105849A1
公开(公告)日：2004-06-03
申请号：US10721720
申请日：2003-11-25
发明人： Antonia C. Kaloidis
IPC分类号： A61K045/00 , A61K031/7048 , A61K031/715 , A61K031/375 , A61K031/353
CPC分类号： A61K45/06 , A61K31/352 , A61K31/375 , A61K31/732 , A61K35/744 , A61K35/745 , A61K35/747 , A61K38/465 , A61K38/47 , A61K38/48 , A61K2300/00
摘要： There is provided compositions for the treatment of the genetic motor neuron disease Spinal Muscular Atrophy (SMA) and methods of using such compositions. The compositions preferably comprise vitamin C and at least two ingredients selected from the group consisting of: flavonoid, pectin, enteric bacterium, enzyme supplement, and any combinations thereof.
摘要翻译：提供了用于治疗遗传运动神经元疾病脊髓性肌萎缩（SMA）的组合物和使用这种组合物的方法。组合物优选包含维生素C和至少两种选自以下的成分：黄酮，果胶，肠细菌，酶补充剂及其任何组合。

45. 发明申请

US20040102415A1 Composition and methods for tissue preservation 有权
标题翻译：组织保存的组成和方法
公开(公告)号：US20040102415A1
公开(公告)日：2004-05-27
申请号：US10257176
申请日：2003-07-14
发明人： Hemant Thatte , Kunda Biswas , Shukri Khuri , Thomas Michel
IPC分类号： A61K038/05 , A61K031/70 , A61K031/727 , A61K031/375 , A61K031/198
CPC分类号： A01N1/02 , A01N1/0226 , A01N1/0247 , A61K9/0009 , A61K31/198 , A61K31/375 , A61K31/70 , A61K31/727 , A61K35/44 , A61K38/063 , A61K38/58 , Y10S623/916 , A61K2300/00
摘要： The present invention provides for compositions and methods for the preservation of tissues and organs ex vivo and in situ. In addition, the present invention provides for kits that may be used in the preparation of the solutions of the present invention. The present invention also provides a device for perfusing tissues and organs with the solutions of the present invention.
摘要翻译：本发明提供了离体和原位保存组织和器官的组合物和方法。此外，本发明提供了可用于制备本发明的溶液的试剂盒。本发明还提供了用本发明的溶液灌注组织和器官的装置。

46. 发明申请

US20040101575A1 Comprehensive pharmacologic therapy for treatment of obesity 审中-公开
标题翻译：综合药理治疗肥胖症
公开(公告)号：US20040101575A1
公开(公告)日：2004-05-27
申请号：US10715912
申请日：2003-11-18
发明人： Martin C. Hinz
IPC分类号： A61K033/06 , A61K031/375 , A61K031/343 , A61K031/198
CPC分类号： A61K31/34 , A61K31/198 , A61K31/343 , A61K31/375 , A61K31/405 , A61K31/4415 , A61K33/06 , Y10S514/905 , Y10S514/909 , Y10S514/91 , A61K31/44 , A61K31/195 , A61K31/135 , A61K2300/00
摘要： The comprehensive pharmacologic therapy for treatment of obesity is a procedure which involves the administration of a desired therapeutic range of Diethylpropion and/or Phentermine in combination with a SSRI medication and nutritional supplementation for brief and long durations which may be 12 months or more. The preferred procedure involves the administration of drugs in combination which are identified as: Citalopram (Celexa) and Phentermine; Citalopram (Celexa) and Diethylpropion; Citalopram (Celexa), Phentermine, and Diethylpropion. In addition nutritional supplementation such as a multivitamin, 5-Hydroxytryptophan, vitamin B6, vitamin C, Tyrosine, Calcium, and Lysine may be used to enhance the performance of the weight loss treatment program.
摘要翻译：用于治疗肥胖症的综合药理学疗法是一种方法，其涉及施用期望的治疗范围的二乙基丙酸和/或苯丁胺与SSRI药物和营养补充剂组合，用于短暂和长时间，其可能为12个月或更长。优选的方法包括组合给药，其被鉴定为：西酞普兰（Celexa）和苯丁胺; 西酞普兰（Celexa）和二乙基丙酸酯; 西酞普兰（Celexa），苯丁胺和二乙基丙酸。此外，还可以使用营养补充剂如多种维生素，5-羟色氨酸，维生素B6，维生素C，酪氨酸，钙和赖氨酸来增强减肥治疗程序的性能。

47. 发明申请

US20040034094A1 Vitamin C stabilized topical formulation 审中-公开
标题翻译：维生素C稳定局部制剂
公开(公告)号：US20040034094A1
公开(公告)日：2004-02-19
申请号：US10223671
申请日：2002-08-16
发明人： Shyam K. Gupta
IPC分类号： A61K031/375 , A61K007/00
CPC分类号： A61K8/676 , A61K8/345 , A61K8/466 , A61K31/375 , A61K2800/522 , A61Q19/00
摘要： A topical formulation produces a surprising result by stabilizing the ascorbic acid in the formulation even though a significant amount of water is present in the formulation. The formulation includes at least one surfactant and at least one water miscible organic solvent and enables water soluble compositions to be incorporated in the formulation.
摘要翻译：局部配方通过稳定制剂中的抗坏血酸产生惊人的结果，即使制剂中存在大量的水。该制剂包括至少一种表面活性剂和至少一种与水可混溶的有机溶剂，并且使水溶性组合物能够掺入制剂中。

48. 发明申请

US20040028675A1 Compositions for the treatment of lupus 审中-公开
标题翻译：用于治疗狼疮的组合物
公开(公告)号：US20040028675A1
公开(公告)日：2004-02-12
申请号：US10426460
申请日：2003-04-30
申请人： Zarlink Semiconductor AB
发明人： Randy H. Ziegler
IPC分类号： A61K038/46 , A61K031/7048 , A61K031/375 , A61K031/353
CPC分类号： A61K31/375 , A61K31/352 , A61K31/353 , A61K31/7048 , A61K38/4873 , A61K2300/00
摘要： A composition and a method for the amelioration of Lupus, related rheumatic and autoimmune diseases such as fibromyalgia and inflammatory joint diseases. The composition consists of a bioflavonoid combined with Bromelain. Vitamin C may be added to the composition to improve its efficacy. The preferred flavonoid is Luteolin or Quercetin. Myricetin may also be used as may be a glycoside such as Rutin that contains either Luteolin, Quercetin or Myricetin as an aglycone. Other effective flavonoids can be selected by their ability to interact with the Kv1.3 channel of lymphocytes. In a preferred method of treatment a mixture of flavonoid, Bromelain and Vitamin C is administered at least daily by an oral route. A mixture of 500 mg Quercetin, 500 mg Bromelain and 500 mg Vitamin C administered three times daily is effective.
摘要翻译：用于改善狼疮，相关风湿性和自身免疫疾病如纤维肌痛和炎性关节疾病的组合物和方法。组合物由生物类黄酮与菠萝蛋白酶组合组成。可以将维生素C加入到组合物中以改善其功效。优选的类黄酮是木犀草素或槲皮素。也可以使用杨梅素作为糖苷例如含有木犀草素，槲皮素或杨梅素作为糖苷配基的芦丁。其他有效的黄酮可以通过与淋巴细胞的Kv1.3通道相互作用的能力来选择。在优选的治疗方法中，通过口服途径至少每天施用类黄酮，菠萝蛋白酶和维生素C的混合物。每天三次施用500mg槲皮素，500mg菠萝蛋白酶和500mg维生素C的混合物是有效的。

49. 发明申请

US20040013747A1 Transdermal pharmaceutical delivery composition 有权
标题翻译：透皮药物输送组合物
公开(公告)号：US20040013747A1
公开(公告)日：2004-01-22
申请号：US10363439
申请日：2003-06-16
发明人： Arthur T. Tucker , Nigel Benjamin
IPC分类号： A61K033/00 , A61K031/56 , A61K031/60 , A61K031/375
CPC分类号： A61K9/06 , A61K9/0014 , A61K47/02 , A61K47/22 , Y02A50/409 , Y02A50/411 , Y02A50/491
摘要： A pharmaceutically delivery system is described comprising a pharmaceutically active agent and acidified nitrite as an agent to produce local production of nitric oxide at the skin surface. The dosage form may be in any pharmaceutically acceptable carrier means and comprises an acidifying agent adapted to reduce the pH at the environment. In one embodiment, a barrier consisting of a membrane allows diffusions of the anaesthetic and nitrite ions while preventing direct contact of the skin and acidifying agent.
摘要翻译：描述了药物递送系统，其包含药物活性剂和酸化亚硝酸盐作为试剂以在皮肤表面产生局部产生一氧化氮。剂型可以是任何药学上可接受的载体，并且包含适于降低环境pH值的酸化剂。在一个实施方案中，由膜组成的屏障允许麻醉剂和亚硝酸根离子的扩散，同时防止皮肤和酸化剂的直接接触。

50. 发明申请

US20040009217A1 Therapeutic liposome composition and method 失效
标题翻译：治疗脂质体组成及方法
公开(公告)号：US20040009217A1
公开(公告)日：2004-01-15
申请号：US10616094
申请日：2003-07-08
发明人： Francis J. Martin , Samuel Zalipsky , Shi Kun Huang
IPC分类号： A61K009/127 , A61K039/00 , A61K038/05 , A61K031/375 , A61K031/198
CPC分类号： A61K9/1273 , A61K9/1271
摘要： A method of liposome-based therapy for a mammalian subject is disclosed. The method uses liposomes with outer surfaces that contain an affinity moiety effective to bind specifically to a biological surface at which the therapy is aimed, and a hydrophilic polymer coating effective to shield the affinity moiety from interaction with the target surface. The hydrophilic polymer coating is made up of polymer chains covalently linked to surface lipid components in the liposomes through releasable linkages. After a desired liposome biodistribution is achieved, a releasing agent is administered to cause cleaving of a substantial portion of the releasable linkages in the liposomes, to expose the affinity agent to the target surface.
摘要翻译：公开了一种哺乳动物受试者基于脂质体的治疗方法。该方法使用具有外表面的脂质体，其具有有效结合治疗目的的生物表面的亲和部分，以及有效屏蔽亲和部分与靶表面相互作用的亲水性聚合物涂层。亲水性聚合物涂层由通过可释放键连接到脂质体中的表面脂质组分的聚合物链组成。在实现期望的脂质体生物分布之后，施用释放剂以引起脂质体中大部分可释放连接的切割，以将亲和剂暴露于靶表面。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式